See more : Shougang Fushan Resources Group Limited (FSHYF) Income Statement Analysis – Financial Results
Complete financial analysis of Bruker Corporation (BRKR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bruker Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- New Residential Investment Corp. (NRZ-PA) Income Statement Analysis – Financial Results
- 23andMe Holding Co. (ME) Income Statement Analysis – Financial Results
- cBrain A/S (0DWV.L) Income Statement Analysis – Financial Results
- Globe Union Industrial Corp. (9934.TW) Income Statement Analysis – Financial Results
- Stagwell Inc. (STGW) Income Statement Analysis – Financial Results
Bruker Corporation (BRKR)
About Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.96B | 2.53B | 2.42B | 1.99B | 2.07B | 1.90B | 1.77B | 1.61B | 1.62B | 1.81B | 1.84B | 1.79B | 1.65B | 1.30B | 1.11B | 1.11B | 547.58M | 435.83M | 297.57M | 284.42M | 260.68M | 116.37M | 92.69M | 76.60M | 64.69M | 42.21M |
| Cost of Revenue | 1.45B | 1.23B | 1.21B | 1.05B | 1.08B | 995.60M | 952.90M | 868.80M | 915.20M | 1.05B | 1.03B | 960.00M | 899.20M | 698.90M | 595.90M | 602.10M | 294.44M | 236.50M | 171.76M | 165.94M | 144.83M | 55.87M | 43.59M | 35.59M | 28.13M | 0.00 |
| Gross Profit | 1.51B | 1.31B | 1.21B | 939.80M | 995.30M | 900.00M | 813.00M | 742.50M | 708.60M | 763.30M | 805.20M | 831.40M | 752.50M | 606.00M | 518.60M | 505.00M | 253.14M | 199.33M | 125.81M | 118.48M | 115.85M | 60.50M | 49.10M | 41.02M | 36.56M | 42.21M |
| Gross Profit Ratio | 51.05% | 51.59% | 50.03% | 47.29% | 48.02% | 47.48% | 46.04% | 46.08% | 43.64% | 42.20% | 43.78% | 46.41% | 45.56% | 46.44% | 46.53% | 45.61% | 46.23% | 45.74% | 42.28% | 41.66% | 44.44% | 51.99% | 52.97% | 53.54% | 56.51% | 100.00% |
| Research & Development | 294.80M | 235.90M | 220.80M | 198.00M | 187.70M | 173.40M | 162.70M | 149.00M | 145.70M | 174.20M | 190.50M | 195.30M | 177.20M | 141.40M | 126.40M | 133.80M | 58.47M | 49.96M | 41.36M | 43.22M | 38.03M | 20.73M | 18.47M | 20.03M | 15.14M | 0.00 |
| General & Administrative | 730.10M | 610.80M | 564.50M | 477.80M | 500.20M | 444.70M | 415.90M | 390.50M | 392.20M | 451.00M | 437.90M | 442.40M | 406.60M | 303.10M | 69.50M | 254.50M | 140.04M | 112.99M | 73.81M | 76.38M | 77.76M | 33.82M | 27.72M | 20.25M | 14.76M | 0.00 |
| Selling & Marketing | 0.00 | -3.40M | -3.30M | -9.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00M | -5.80M | 185.80M | 183.80M | 105.98M | 84.01M | 51.44M | 55.98M | 60.42M | 26.81M | 21.71M | 0.00 | 0.00 | 0.00 |
| SG&A | 730.10M | 607.40M | 561.20M | 468.60M | 500.20M | 444.70M | 415.90M | 390.50M | 392.20M | 451.00M | 437.90M | 442.40M | 403.60M | 297.30M | 255.30M | 254.50M | 140.04M | 112.99M | 73.81M | 76.38M | 77.76M | 33.82M | 27.72M | 20.25M | 14.76M | 0.00 |
| Other Expenses | 52.20M | -29.70M | -14.30M | -24.90M | -6.50M | -19.50M | -19.70M | -25.80M | -20.40M | -21.20M | -28.60M | -13.90M | 13.10M | 5.80M | 200.00K | 8.50M | 4.66M | 5.72M | 0.00 | 0.00 | 9.75M | 202.00K | -356.00K | 0.00 | 3.49M | 42.37M |
| Operating Expenses | 1.08B | 843.30M | 782.00M | 666.60M | 687.90M | 618.10M | 578.60M | 539.50M | 537.90M | 625.20M | 628.40M | 637.70M | 596.90M | 450.30M | 255.30M | 388.30M | 198.51M | 162.95M | 115.17M | 119.59M | 125.53M | 54.75M | 45.83M | 40.28M | 33.38M | 42.37M |
| Cost & Expenses | 2.53B | 2.07B | 1.99B | 1.71B | 1.77B | 1.61B | 1.53B | 1.41B | 1.45B | 1.67B | 1.66B | 1.60B | 1.50B | 1.15B | 851.20M | 990.40M | 492.95M | 399.45M | 286.93M | 285.53M | 270.36M | 110.62M | 89.42M | 75.87M | 61.51M | 42.37M |
| Interest Income | 11.20M | 4.10M | 900.00K | 3.20M | 1.30M | 1.20M | 800.00K | 300.00K | 1.20M | 800.00K | 1.00M | 900.00K | 1.00M | 900.00K | 1.00M | 4.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 16.40M | 16.10M | 14.30M | 14.40M | 16.00M | 12.60M | 15.40M | 13.20M | 13.00M | 13.30M | 13.40M | 14.30M | 7.30M | 5.60M | 7.50M | 40.50M | 11.84M | 3.96M | 0.00 | 3.85M | 6.36M | 20.15M | 0.00 | 0.00 | 1.35M | 0.00 |
| Depreciation & Amortization | 114.90M | 88.80M | 89.20M | 80.50M | 75.60M | 64.90M | 63.90M | 54.30M | 53.30M | 59.70M | 61.30M | 59.10M | 3.00M | 5.80M | 29.70M | 29.90M | 12.63M | 13.29M | 8.61M | 9.79M | 16.87M | 8.20M | 6.04M | 4.15M | 3.49M | 0.00 |
| EBITDA | 599.00M | 545.30M | 497.10M | 320.70M | 380.00M | 340.10M | 299.50M | 262.10M | 235.90M | 215.60M | 239.10M | 211.70M | 205.70M | 155.70M | 166.30M | 134.80M | 63.07M | 49.87M | 19.25M | 8.68M | 697.00K | 17.47M | 10.30M | 4.88M | 6.66M | -161.00K |
| EBITDA Ratio | 20.21% | 21.75% | 21.37% | 17.79% | 18.48% | 18.29% | 16.89% | 15.97% | 14.08% | 11.57% | 12.94% | 12.14% | 9.60% | 12.38% | 35.67% | 14.75% | 13.29% | 11.85% | 6.47% | 3.05% | 5.91% | 20.80% | 9.68% | 6.64% | 10.93% | -0.38% |
| Operating Income | 436.90M | 432.70M | 413.30M | 248.30M | 300.90M | 262.40M | 214.70M | 177.20M | 145.70M | 105.40M | 148.20M | 156.00M | 155.60M | 155.70M | 136.70M | 108.20M | 49.97M | 30.66M | 10.64M | -1.12M | -9.68M | 5.75M | 3.27M | 734.00K | 3.18M | -161.00K |
| Operating Income Ratio | 14.74% | 17.10% | 17.09% | 12.49% | 14.52% | 13.84% | 12.16% | 11.00% | 8.97% | 5.83% | 8.06% | 8.71% | 9.42% | 11.93% | 12.27% | 9.77% | 9.13% | 7.04% | 3.57% | -0.39% | -3.71% | 4.94% | 3.53% | 0.96% | 4.91% | -0.38% |
| Total Other Income/Expenses | 107.30M | -18.80M | -19.70M | -22.50M | -20.50M | -17.70M | -21.70M | -4.20M | -17.70M | -4.10M | -23.60M | -17.70M | -10.10M | -5.60M | -7.60M | -15.00M | -89.09M | 3.76M | -780.00K | -3.78M | 1.85M | -9.88M | 2.73M | 1.59M | -1.32M | 161.00K |
| Income Before Tax | 544.20M | 413.90M | 393.60M | 225.80M | 280.40M | 244.70M | 197.80M | 177.60M | 128.00M | 101.30M | 124.60M | 138.30M | 145.50M | 150.10M | 129.10M | 93.20M | 48.61M | 34.42M | 11.95M | -4.90M | -7.83M | -4.14M | 6.01M | 2.32M | 1.86M | 0.00 |
| Income Before Tax Ratio | 18.36% | 16.36% | 16.28% | 11.36% | 13.53% | 12.91% | 11.20% | 11.02% | 7.88% | 5.60% | 6.77% | 7.72% | 8.81% | 11.50% | 11.58% | 8.42% | 8.88% | 7.90% | 4.02% | -1.72% | -3.00% | -3.56% | 6.48% | 3.03% | 2.88% | 0.00% |
| Income Tax Expense | 117.70M | 116.40M | 113.00M | 64.40M | 82.40M | 63.70M | 117.50M | 23.10M | 23.10M | 41.70M | 42.80M | 60.10M | 51.50M | 53.30M | 48.10M | 28.00M | 16.78M | 15.93M | 8.26M | 2.87M | 9.72M | 2.06M | 2.37M | 254.00K | 986.89K | 0.00 |
| Net Income | 427.20M | 296.60M | 277.10M | 157.80M | 197.20M | 179.70M | 78.60M | 153.60M | 101.60M | 56.70M | 80.10M | 77.50M | 92.30M | 95.40M | 81.20M | 64.90M | 31.53M | 18.48M | 3.65M | -7.83M | -17.55M | -6.20M | 3.64M | 2.25M | 1.25M | 0.00 |
| Net Income Ratio | 14.41% | 11.72% | 11.46% | 7.94% | 9.51% | 9.48% | 4.45% | 9.53% | 6.26% | 3.13% | 4.35% | 4.33% | 5.59% | 7.31% | 7.29% | 5.86% | 5.76% | 4.24% | 1.23% | -2.75% | -6.73% | -5.33% | 3.92% | 2.94% | 1.93% | 0.00% |
| EPS | 2.92 | 2.00 | 1.83 | 1.03 | 1.27 | 1.15 | 0.50 | 0.95 | 0.60 | 0.34 | 0.48 | 0.47 | 0.56 | 0.58 | 0.50 | 0.40 | 0.61 | 0.18 | 0.10 | -0.08 | -0.17 | -0.12 | -0.05 | 0.04 | 0.03 | 0.00 |
| EPS Diluted | 2.90 | 1.99 | 1.81 | 1.02 | 1.26 | 1.14 | 0.49 | 0.95 | 0.60 | 0.33 | 0.48 | 0.46 | 0.55 | 0.58 | 0.49 | 0.39 | 0.60 | 0.18 | 0.10 | -0.08 | -0.17 | -0.12 | -0.05 | 0.04 | 0.03 | 0.00 |
| Weighted Avg Shares Out | 146.40M | 148.60M | 151.40M | 153.40M | 155.20M | 156.20M | 158.10M | 161.40M | 168.20M | 167.80M | 166.50M | 166.00M | 165.40M | 164.40M | 163.50M | 162.70M | 161.20M | 101.51M | 100.82M | 96.38M | 103.26M | 52.60M | 54.06M | 56.25M | 45.50M | 45.50M |
| Weighted Avg Shares Out (Dil) | 147.20M | 149.40M | 152.90M | 154.60M | 156.60M | 157.20M | 159.10M | 162.20M | 169.10M | 169.50M | 168.50M | 167.40M | 166.90M | 165.70M | 164.90M | 165.60M | 164.30M | 102.56M | 101.13M | 96.38M | 103.26M | 52.60M | 54.06M | 56.25M | 45.50M | 45.50M |
Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors
Bruker Introduces Innovative Neuroscience Research Solution with High-Speed OptoVolt Voltage Imaging
Here's Why You Should Retain BRKR Stock in Your Portfolio Now
Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery
Is the Options Market Predicting a Spike in Bruker (BRKR) Stock?
Assessment of the Dermatology Diagnostic Devices Market, 2020-2030, Featuring Strategic Analysis of Canfield Scientific, Leica Microsystems, Welch Allyn, Bruker, Heine Optotechnik & More
Biognosys Enters Reselling Agreement for Spectronaut Proteomics Software with Leading Provider of Mass Spectrometry Systems
Bruker (BRKR) Up 6.8% Since Last Earnings Report: Can It Continue?
Should You Consider Retaining Bruker Stock in Your Portfolio Now?
Biognosys Announces Commercial Availability of NULISA™ Proteomics Assay Services for Biomarker Research
Source: https://incomestatements.info
Category: Stock Reports